Replies to post #6726 on China Growth Stocks

[BiotechValues]

yes, it is a good presentation. Matt Hayden and HC International are top tier.

And yes, CSOL is very undervalued compared to most other microcaps that have run now...although I found it undervalued even before the runs of stocks like JADA, CHFI, etc.

hell, CSOL has a $7.6M market cap and about $6.8M cash ($4.2M cash from the non-profitable subsidiary they've divested themselves of) pls $2.6M existing cash last filing.

BV is $1.70, and stock at .50, eps positive again, positive cash flows, decent forward looking statements and zero debt.

I don't know if the market is missing something, or maybe I am (I've been wrong before!)

But in my experience, whenever I bought a company that is eps positive, zero debt, and at less than half of book value, I've done well- it just takes more time with stocks like CSOL that have a crappy website and no IR team to give it exposure.



Here's the q2 filing

http://ih.advfn.com/p.php?pid=nmona&cb=1256060201&article=38999629&symbol=NB%5ECSOL